HLA-E and cancer: -Some preclinical studies have already shown that blocking HLA-E through antibodies (58, 59) or downregulating HLA-E expression through the approved anti-cancer drugs selinexor and bortezomib (60, 61) enhance NK cell cytotoxic activity in solid tumor.